Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized Study of the Southern Italy Cooperative Oncology Group

Pasquale Comella, Giuseppe Frasci, Nicola Panza, Luigi Manzione, Vito Lorusso, Gaetano Di Rienzo, Riccardo Cioffi, Giuseppe De Cataldis, Luigi Maiorino, Domenico Bilancia, Gianpaolo Nicolella, Michele Natale, Franco Carpagnano, Carmen Pacilio, Mario De Lena, Andrea Bianco, Giuseppe Comella

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: In a previous phase I study cisplatin (CDDP), gemcitabine (GEM), and vinorelbine (VNR) combination therapy was safe and very active in patients with non-small-cell lung cancer (NSCLC). This study was aimed at better defining the activity and toxicity of this regimen. Patients and Methods: One hundred eleven chemotherapy-naive patients, age ≤ 70 years, with stage IIIB or IV NSCLC and a performance status of 0 or 1 (Eastern Cooperative Oncology Group scale) were randomized to two treatment arms. Patients on arm A received CDDP 50 mg/m2, GEM 1,000 mg/m2, and VNR 25 mg/m2 on days 1 and 8 of an every-3-weeks cycle (57 patients). Patients on arm B received CDDP 80 mg/m2, epirubicin 80 mg/m2, and vindesine 3 mg/m2, all delivered on day 1 every 4 weeks, plus Ionidamine orally 150 mg three times daily (54 patients). In December 1996, randomization was stopped early, and an additional 30 patients were treated with the experimental regimen to obtain a more accurate estimation of its activity rate. Results: Among 87 patients who received the CDDPGEM-VNR combination, four complete responses (CRs) and 46 partial responses (PRs) were observed, for an overall response rate of 57% (95% confidence interval [CI], 46% to 68%). Two CRs and 18 PRs were recorded among 54 patients on arm B, giving a 37% activity rate (95% CI, 24% to 51%). After a median follow-up duration of 19 months, the median progression-free and overall survival durations were 32 and 50 weeks in arm A, and 18 and 33 weeks in arm B, respectively. World Health Organization grade 3 to 4 neutropenia and thrombocytopenia occurred in 46% and 14% of patients in arm A and in 22% and 11% of those in arm B, respectively. Severe nonhematologic toxicity was uncommon in both arms. Conclusion: The CDDP-GEM- VNR combination is a highly effective treatment for patients with advanced NSCLC and has a manageable toxicity. A phase III trial comparing this new combination with both CDDP-VNR and CDDP-GEM regimens is underway.

Original languageEnglish
Pages (from-to)1526-1534
Number of pages9
JournalJournal of Clinical Oncology
Volume17
Issue number5
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A phase II randomized Study of the Southern Italy Cooperative Oncology Group'. Together they form a unique fingerprint.

Cite this